The CNOT4 Knockout Raji Polyclonal Cells product constitutes a CRISPR/Cas9-edited polyclonal knockout cell population in which the CNOT4 gene has been disrupted. This cell pool enables researchers to investigate the loss-of-function consequences of CNOT4 in a heterogeneous B-lymphocyte background. As a polyclonal population, the product reflects a diverse spectrum of editing events, providing a robust system for studying gene function without the biases of clonal selection. The knockout model serves as a foundational tool for dissecting post-transcriptional gene regulation mechanisms in a lymphoma-relevant cellular context.
The Raji host cell line originates from a Burkitt lymphoma patient and exhibits characteristics of mature B lymphocytes, including antibody production and antigen presentation capabilities. Derived from a lymphoblastoid cell line, Raji cells are widely used in immunology and cancer research due to their rapid proliferation and expression of key B-cell markers. They provide a physiologically relevant environment for studying oncogenic signaling pathways and mRNA metabolism, as disruptions in post-transcriptional control frequently drive malignant transformation in lymphoid tissues.
CNOT4 encodes a subunit of the CCR4-NOT deadenylase complex, which catalyzes the removal of poly(A) tails from mRNAs, triggering translational repression and mRNA decay. Additionally, CNOT4 possesses E3 ubiquitin-protein ligase activity, targeting proteins for proteasomal degradation. CNOT4 interacts with core complex members CNOT1, CNOT7, and CNOT8, and regulatory partners such as BTG2 and TOB1. It functions downstream of TGF-beta and Wnt ligands, and modulates the stability of mRNAs encoding c-MYC, Cyclin D1, BCL2, and CDKN1A. Through these dual enzymatic activities, CNOT4 orchestrates post-transcriptional gene expression programs that control cell proliferation and survival.
In the Raji B-cell lymphoma context, CNOT4 disruption is particularly informative for dissecting pathways that sustain oncogenic growth. The CCR4-NOT complex, together with the PAN2-PAN3 deadenylase and the DCP1-DCP2 decapping complex, regulates mRNA turnover of key regulators. By eliminating CNOT4 function, researchers can examine how altered mRNA stability and ubiquitin-dependent proteolysis contribute to dysregulated expression of oncogenes and tumor suppressors in lymphoma. This model is valuable for understanding how post-transcriptional mechanisms intersect with TGF-beta and Wnt signaling to influence Burkitt lymphoma pathogenesis.
Typical applications include investigating mRNA half-life via RT-qPCR or global transcriptomic changes through RNA-seq, assessing ubiquitination activity in immunoprecipitation-based assays, and evaluating functional impacts on cell proliferation and apoptosis using flow cytometry. The polyclonal knockout population enables drug target validation screens and mechanistic studies of mRNA surveillance pathways in a lymphoma setting. Researchers may further examine interactions between CNOT4 and the PAN2-PAN3 deadenylase or decapping machinery. For detailed technical specifications, please contact Ascent Research.
